J.P. Morgan analyst Cory Kasimov maintained a Buy rating on NovoCure Ltd (NVCR) on May 2 and set a price target of $61. The company’s shares closed yesterday at $48.92.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 0.6% and a 41.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.
NovoCure Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $61, which is a 24.7% upside from current levels. In a report issued on May 3, Mizuho Securities also maintained a Buy rating on the stock with a $63 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $56.67 and a one-year low of $26.02. Currently, NovoCure Ltd has an average volume of 588.3K.
Based on the recent corporate insider activity of 101 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
